# Bitopertin

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/bitopertin
Canonical HTML page: https://getbiobrief.com/entity/bitopertin

## Timeline

- **2026-10-01**: APOLLO Trial Data — Expected top-line results from the Phase 2/3 APOLLO trial in Q4 2026.
- **2026-02-23**: Regulatory Pivot — Disc Medicine announces shift to traditional approval pathway.
- **2026-02-18**: FDA CRL Issued — FDA rejects accelerated approval pathway for bitopertin in EPP.

## Recent coverage (1 stories)

### Disc Medicine Pivots to Traditional FDA Pathway for Bitopertin After CRL
2026-02-23 22:44:54 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Disc Medicine has shifted its regulatory strategy for bitopertin in erythropoietic protoporphyria (EPP) following an FDA Complete Response Letter regarding its accelerated approval bid. The company will now focus on a traditional approval route, with pivotal Phase 2/3 APOLLO trial data expected in Q4 2026.
Full story: https://getbiobrief.com/story/disc-medicine-bitopertin-fda-crl-apollo-trial

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.